KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Capital Leases (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Capital Leases data on record, last reported at $54.9 million in Q4 2025.

  • For Q4 2025, Capital Leases fell 3.45% year-over-year to $54.9 million; the TTM value through Dec 2025 reached $54.9 million, down 3.45%, while the annual FY2025 figure was $54.9 million, 3.45% down from the prior year.
  • Capital Leases reached $54.9 million in Q4 2025 per AMRX's latest filing, down from $55.7 million in the prior quarter.
  • Across five years, Capital Leases topped out at $61.9 million in Q1 2021 and bottomed at $54.9 million in Q4 2025.
  • Average Capital Leases over 5 years is $58.9 million, with a median of $59.4 million recorded in 2023.
  • Peak YoY movement for Capital Leases: surged 2912.55% in 2021, then dropped 3.75% in 2025.
  • A 5-year view of Capital Leases shows it stood at $60.3 million in 2021, then rose by 0.86% to $60.8 million in 2022, then fell by 3.63% to $58.6 million in 2023, then decreased by 2.86% to $56.9 million in 2024, then decreased by 3.45% to $54.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Leases were $54.9 million in Q4 2025, $55.7 million in Q3 2025, and $56.0 million in Q2 2025.